Lancet
-
Randomized Controlled Trial Multicenter Study Comparative Study
Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial.
-
Randomized Controlled Trial Multicenter Study
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
Dual neutralisation of interleukin 17A (IL17A) and interleukin 17F (IL17F) is a potential novel therapeutic approach in psoriatic arthritis. We assessed bimekizumab, a monoclonal antibody that selectively neutralises IL17A and IL17F, in patients with active psoriatic arthritis. ⋯ UCB Pharma.
-
Randomized Controlled Trial Multicenter Study
Prophylactic biological mesh reinforcement versus standard closure of stoma site (ROCSS): a multicentre, randomised controlled trial.
Closure of an abdominal stoma, a common elective operation, is associated with frequent complications; one of the commonest and impactful is incisional hernia formation. We aimed to investigate whether biological mesh (collagen tissue matrix) can safely reduce the incidence of incisional hernias at the stoma closure site. ⋯ National Institute for Health Research Research for Patient Benefit and Allergan.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial.
Acute atrial fibrillation is the most common arrythmia treated in the emergency department. Our primary aim was to compare conversion to sinus rhythm between pharmacological cardioversion followed by electrical cardioversion (drug-shock), and electrical cardioversion alone (shock-only). Our secondary aim was to compare the effectiveness of two pad positions for electrical cardioversion. ⋯ Heart and Stroke Foundation of Canada and the Canadian Institutes of Health Research.
-
Randomized Controlled Trial Multicenter Study
Deep learning for prediction of colorectal cancer outcome: a discovery and validation study.
Improved markers of prognosis are needed to stratify patients with early-stage colorectal cancer to refine selection of adjuvant therapy. The aim of the present study was to develop a biomarker of patient outcome after primary colorectal cancer resection by directly analysing scanned conventional haematoxylin and eosin stained sections using deep learning. ⋯ The Research Council of Norway.